Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Study of Dasatinib and Osimertinib (AZD9291) in Patients With Advanced Non-small Cell Lung Cancer With EGFR Mutations

NCT02954523 is registered in ClinicalTrials.gov with Chul Kim as lead sponsor.

NCT NCT02954523
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02954523 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Study of Dasatinib and Osimertinib (AZD9291) in Patients With Advanced Non-small Cell Lung Cancer With EGFR Mutations
Lead sponsor
Chul Kim
Phase
Phase 1/2
Overall status
Terminated
Start date
October 31, 2016
Completion date
March 3, 2023
Enrollment
10 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

egfr gene mutation, nonsmall cell lung cancer